Chembio Diagnostics (NASDAQ:CEMI) will release its earnings data after the market closes on Thursday, November 8th. Analysts expect Chembio Diagnostics to post earnings of ($0.15) per share for the quarter.
Chembio Diagnostics (NASDAQ:CEMI) last issued its earnings results on Wednesday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.05). The firm had revenue of $8.72 million during the quarter, compared to analysts’ expectations of $6.94 million. Chembio Diagnostics had a negative return on equity of 26.91% and a negative net margin of 16.54%. On average, analysts expect Chembio Diagnostics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of CEMI opened at $7.00 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.58 and a current ratio of 3.53. Chembio Diagnostics has a twelve month low of $5.97 and a twelve month high of $11.55.
Separately, Benchmark began coverage on Chembio Diagnostics in a research report on Wednesday, July 11th. They issued a “buy” rating and a $14.00 target price on the stock.
In other news, insider Robert Passas bought 15,000 shares of the business’s stock in a transaction that occurred on Monday, November 5th. The shares were acquired at an average cost of $6.75 per share, with a total value of $101,250.00. Following the transaction, the insider now owns 15,000 shares of the company’s stock, valued at approximately $101,250. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.65% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/11/07/chembio-diagnostics-cemi-scheduled-to-post-quarterly-earnings-on-thursday.html.
Chembio Diagnostics Company Profile
Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi.
Further Reading: Discover Your Risk Tolerance
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.